ORGANIZATION

Wholesalers Ask for Prioritized Drug Supply for Disaster Areas; Emergency Dispensing Scheme Begins

January 11, 2024

The Federation of Japan Pharmaceutical Wholesalers Association (JPWA) and an association of drug distributors in Ishikawa Prefecture on January 9 requested pharma companies to provide needed medicines to quake-hit central Japan areas on a priority basis.

Since a great deal of efforts are being made to secure the supply of products under shipment restrictions, they asked for the prioritized provisioning of these products as well as other needed drugs to the disaster areas.

The request was issued to the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) as well as individual drug makers. Pharma companies told the wholesaler groups that they would do their best to meet the request, according to the Ishikawa association.

On January 10, the Japan Pharmaceutical Manufacturers Association (JPMA) issued a statement vowing to strive for the stable supply of needed medicines to the affected regions in collaboration with the FPMAJ and wholesaler partners in order to meet the requests of relevant municipalities and medical organizations as well as the Ministry of Health, Labor and Welfare.

Emergency Dispensing Scheme Now in Place

Meanwhile, an emergency dispensing scheme has been introduced in Ishikawa Prefecture. Prescriptions issued by six public hospitals in the northern and central part of the Noto Peninsula can now be filled by a pharmacy in Kanazawa, the capital of the prefecture.

In this scheme, launched on January 5, prescriptions are faxed from the hospital to the pharmacy, and then dispensed medicines are delivered to each hospital via wholesalers with medication guidance provided by pharmacists over the phone or by other means.

As of noon on January 9, only 13 of the 31 pharmacies in the northern part of the peninsula, the area hardest hit by the earthquake, were operational to fill prescriptions.

ORGANIZATION

By Izuru Ando

Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…

By Philip Carrigan

Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

By Izuru Ando

Generic manufacturers in Japan will be required to disclose supply-related information from this June under a new company indicator rule…

The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…